Drug Profile

ABS 101 - Absci Corporation

Alternative Names: ABS-101 - Absci Corporation

Latest Information Update: 02 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AbSci
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Inflammatory bowel diseases

Most Recent Events

12 Nov 2025 ABS 101 - Absci Corporation is available for licensing as of 12 Nov 2025. https://www.absci.com/partnerships/
12 Nov 2025 Pharmacokinetics and adverse events data from a phase I trial in Inflammatory bowel diseases released by AbSci
13 May 2025 Phase-I clinical trials in Inflammatory bowel diseases (In volunteers) in Australia (SC) (ACTRN12625000212459p)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com